ebola
viru
ebov
filamentousenvelop
singlestrand
negativesens
rna
viru
taxonom
classifi
filovirida
date
five
speci
ebolaviru
genu
identifi
includ
zair
sudan
reston
tai
forest
bundibugyo
ebolaviru
ebola
viru
infect
lead
sever
viral
hemorrhag
fever
human
nonhuman
primat
march
outbreak
ebola
virus
began
guinea
caus
case
infect
death
pose
sever
threat
public
health
worldwid
ebola
viru
genom
contain
seven
gene
encod
np
glycoprotein
gp
rnadepend
rna
polymeras
l
viru
protein
infect
host
cell
gp
ebola
virus
first
bind
attach
molecul
integrin
dcsign
lsign
lectin
famili
protein
heparan
sulfat
folat
ebola
virus
intern
macropinocytosi
subsequ
transport
earli
late
endosom
endolysosom
ebola
viru
gp
cleav
cathepsin
l
subsequ
cathepsin
b
expos
receptorbind
domain
bind
specif
receptor
ebola
virus
releas
genom
cytoplasm
host
cell
antiebov
vaccin
drug
extens
develop
two
promis
vaccin
shown
render
nonhuman
primat
resist
ebola
viru
infect
current
clinic
trial
addit
antiebov
monoclon
antibodi
zmapp
sirna
compound
inhibit
ebola
viru
infect
develop
furthermor
sever
clinic
approv
drug
also
report
inhibit
ebola
viru
infect
howev
valu
drug
rel
high
antiebov
drug
potent
inhibitori
activ
urgent
need
facilit
identif
method
high
throughput
screen
clinic
approv
drug
could
appli
immedi
clinic
reason
approach
studi
identifi
teicoplanin
sever
glycopeptid
antibiot
ebola
viru
entri
inhibitor
high
effici
low
cytotox
provid
promis
mean
effect
prophylaxi
treatment
ebola
viru
infect
hela
madindarbi
canin
kidney
cell
line
maintain
dulbecco
modifi
eagl
medium
gibco
fetal
calf
serum
gibco
unitsml
penicillin
streptomycin
gibco
cell
line
maintain
medium
gibco
fetal
calf
serum
unitsml
penicillin
streptomycin
primari
human
umbil
vein
endotheli
cell
maintain
human
endothelialsfm
gibco
ngml
endotheli
cell
growth
supplement
merck
millipor
ngml
recombin
human
fgf
basic
amino
acid
protein
r
system
fetal
calf
serum
unitsml
penicillin
streptomycin
gp
sequenc
zair
chemic
synthes
insert
plasmid
phivluciferas
pcmvvsvg
plasmid
obtain
addgen
plasmid
kindli
provid
dr
trono
plasmid
encod
renilla
luciferas
report
gp
pcaggsnp
pcaggsl
plasmid
produc
describ
previous
pseudotyp
virus
produc
cotransfect
phivluciferas
differ
envelop
plasmid
cell
confluent
plate
lipofectamin
follow
manufactur
instruct
invitrogen
amount
plasmid
list
follow
hivluczair
ebovgp
pseudotyp
virus
phivluciferas
ebovgp
hivlucvsvg
pseudotyp
virus
phivluciferas
pcmvvsvg
hivlucsarscov
pseudotyp
virus
phivluciferas
hivlucmerscov
pseudotyp
virus
phivluciferas
h
supernat
contain
pseudotyp
virus
collect
filter
pores
filter
pall
store
use
ebola
transcript
replicationcompet
viruslik
particl
trvlp
produc
cotransfect
ng
plasmid
encod
renilla
luciferas
report
gene
gp
ng
ng
pcaggsnp
ng
ng
ng
pcaggsl
plasmid
cell
confluent
plate
lipofectamin
invitrogen
h
medium
discard
cell
incub
fresh
medium
h
supernat
contain
ebola
transcript
replicationcompet
viruslik
particl
collect
filter
pores
filter
pall
store
use
high
throughput
screen
fdaapprov
drug
librari
topscienc
conduct
plate
compound
per
well
cell
incub
compound
h
infect
ng
hivluczair
ebovgp
pseudotyp
virus
contain
polybren
h
medium
discard
cell
wash
briefli
pb
incub
fresh
medium
h
intracellular
luciferas
activ
examin
micropl
luminomet
promega
compound
effect
inhibit
luciferas
activ
select
secondari
screen
execut
hivluczair
ebovgp
hivlucvsvg
pseudotyp
virus
similar
procedur
cell
seed
plate
per
well
h
cell
incub
teicoplanin
differ
concentr
h
cell
viabil
determin
aqueou
one
solut
cell
prolifer
assay
promega
cell
seed
plate
per
well
twenti
four
hour
later
cell
infect
hivluczair
ebovgp
pseudotyp
virus
incub
teicoplanin
h
postinfect
h
medium
discard
cell
wash
briefli
pb
incub
fresh
medium
h
intracellular
luciferas
activ
determin
hivlucvsvg
pseudotyp
virus
use
control
specif
cell
seed
plate
per
well
h
cell
incub
teicoplanin
variou
concentr
h
infect
ng
hivluczair
ebovgp
hivlucvsvg
pseudotyp
virus
per
well
virion
entri
assay
h
cell
wash
twice
pb
incub
trypsin
min
remov
virus
adher
cell
surfac
cell
collect
lyse
intracellular
amount
measur
elisa
virion
uptak
assay
h
cell
wash
twice
pb
incub
trypsin
min
remov
virus
adher
cell
surfac
cell
collect
lyse
intracellular
amount
measur
elisa
primari
human
umbil
vein
endotheli
cell
cell
hela
cell
seed
plate
per
well
h
cell
incub
teicoplanin
variou
concentr
h
cell
infect
hivluczair
ebovgp
pseudotyp
virus
h
medium
discard
cell
wash
briefli
pb
incub
fresh
medium
h
intracellular
luciferas
activ
measur
cell
plate
format
per
well
incub
teicoplanin
variou
concentr
h
cell
infect
hivluczair
ebovgp
pseudotyp
virus
h
supernat
remov
centrifug
g
min
cell
suspend
cultur
rpmi
medium
h
intracellular
luciferas
activ
determin
cell
seed
plate
per
well
h
cell
incub
teicoplanin
gradient
concentr
h
cell
infect
hivlucsarscov
hivlucmerscov
pseudotyp
virus
h
medium
discard
cell
wash
briefli
pb
incub
fresh
medium
h
intracellular
luciferas
activ
measur
ebola
trvlp
entri
inhibit
assay
cell
seed
plate
per
well
h
pretransfect
experi
cell
pretransfect
ng
pcaggsnp
ng
ng
ng
pcaggsl
ng
ng
plasmid
lipofectamin
accord
supplier
protocol
invitrogen
h
medium
discard
cell
incub
teicoplanin
gradient
concentr
h
nonpretransfect
experi
cell
directli
incub
teicoplanin
gradient
concentr
h
without
pretransfect
plasmid
cell
infect
ebola
trvlp
h
medium
discard
cell
wash
briefli
pb
incub
fresh
medium
h
intracellular
luciferas
activ
measur
ng
hivluczair
ebovgp
pseudotyp
virus
incub
teicoplanin
plate
h
compoundviru
mixtur
transfer
microcon
centrifug
filter
devic
millipor
centrifug
g
min
afterward
fresh
medium
twice
ad
onto
filter
devic
wash
compoundviru
mixtur
ml
dmem
use
suspend
compoundviru
mixtur
filter
devic
centrifug
revers
g
min
solut
collect
use
infect
cell
normal
h
intracellular
luciferas
activ
measur
compoundcel
pretreat
assay
cell
seed
plate
per
well
h
cell
incub
teicoplanin
variou
concentr
h
medium
discard
cell
twice
wash
pb
incub
fresh
medium
afterward
cell
infect
hivluczair
ebovgp
pseudotyp
virus
twelv
hour
later
medium
discard
cell
wash
briefli
pb
incub
fresh
medium
h
intracellular
luciferas
activ
measur
cell
seed
plate
per
well
h
cell
transfect
sirna
final
concentr
nm
via
rnaimax
accord
supplier
protocol
invitrogen
forti
eight
hour
later
cell
lyse
reagent
invitrogen
isol
total
rna
conduct
accord
supplier
protocol
invitrogen
rna
reversetranscript
primescript
rt
reagent
kit
takara
quantit
rtpcr
conduct
biorad
real
timepcr
detect
system
biorad
sybr
premix
ex
taq
takara
initi
denatur
cdna
perform
min
cycl
procedur
denatur
anneal
extens
perform
primer
human
gapdh
actb
varieti
target
gene
smart
pool
sirna
obtain
ribobio
procedur
previous
describ
follow
minor
modif
briefli
cell
incub
teicoplanin
h
cell
incub
mgml
dextranalexa
fluor
mr
thermo
fisher
scientif
h
serumcontain
dmem
cell
wash
twice
pb
incub
polyformaldehyd
room
temperatur
min
cell
wash
twice
pb
incub
triton
room
temperatur
min
follow
incub
pb
contain
bovin
serum
albumin
room
temperatur
h
afterward
cell
wash
pb
incub
rabbit
antibodi
proteintech
room
temperatur
h
cell
wash
pb
contain
tween
three
time
incub
goat
antirabbit
igg
abcam
room
temperatur
min
follow
wash
pb
contain
tween
three
time
incub
dapi
room
temperatur
min
cell
wash
pb
contain
tween
three
time
imag
obtain
zeiss
confoc
microscopi
use
zeiss
zfn
softwar
coloc
dextran
analyz
field
cell
per
field
per
independ
experi
two
protocol
previous
describ
follow
minor
modif
briefli
cell
seed
black
plate
h
cell
incub
teicoplanin
zphetyr
tbu
diazomethyl
keton
cathepsin
l
inhibitor
iii
millipor
variou
concentr
h
cell
wash
pb
incub
pb
contain
zphearg
per
well
min
afterward
fluoresc
test
fluoromet
excit
nm
emiss
nm
vitro
enzymat
assay
recombin
human
cathepsin
l
rhctsl
sino
biolog
inc
buffer
mm
naoac
mm
edta
ph
contain
teicoplanin
zphetyr
tbu
diazomethyl
keton
incub
h
rhctslcompound
mixtur
incub
zphearg
h
fluoresc
test
fluoromet
excit
nm
emiss
nm
initi
screen
procedur
gener
hivluczair
ebovgp
pseudotyp
virus
virus
allow
infect
cell
presenc
fdaapprov
drug
librari
compound
inhibit
viru
luciferas
activ
identifi
initi
hit
shown
tabl
identifi
hit
could
inhibit
entri
hivluczair
ebovgp
pseudotyp
virus
exclud
hit
inhibit
earli
event
life
cycl
identifi
ebovgpspecif
drug
hivlucvsvg
pseudotyp
virus
bear
vesicular
stomat
viru
vsv
glycoprotein
use
secondari
screen
initi
hit
compound
final
two
drug
act
specif
ebola
viru
entri
inhibitor
identifi
teicoplanin
amiodaron
fig
teicoplanin
glycopeptid
antibiot
includ
five
major
compon
base
differ
side
chain
fig
demonstr
inhibitori
effect
hivluczair
ebovgp
pseudotyp
virus
fig
cytotox
teicoplanin
also
determin
use
cell
viabil
assay
greater
fig
confirm
whether
teicoplanin
act
ebola
viru
entri
inhibitor
timeofaddit
assay
conduct
data
show
teicoplanin
repress
entri
ebola
virus
earli
stage
ebola
viru
infect
fig
addit
virion
entri
assay
also
demonstr
teicoplanin
inhibit
entri
hivluczair
ebovgp
pseudotyp
virus
dosedepend
manner
howev
teicoplanin
repress
entri
hivlucvsvg
pseudotyp
virus
fig
ebola
virus
infect
wide
rang
host
cell
includ
vascular
endotheli
cell
epitheli
cell
monocyt
account
pathogenesi
observ
ebolainfect
patient
thu
import
examin
whether
teicoplanin
could
repress
entri
ebola
virus
differ
type
cell
data
show
teicoplanin
effect
repress
viru
entri
primari
human
umbil
vein
endotheli
cell
fig
human
epitheli
cell
line
fig
hela
cell
fig
human
acut
monocyt
leukemia
cell
line
fig
elucid
molecular
mechan
antiebola
viru
activ
teicoplanin
necessari
determin
whether
target
teicoplanin
locat
directli
viru
compound
viru
preincub
assay
demonstr
teicoplanin
preincub
ebolahiv
pseudotyp
virus
filter
wash
away
inhibitori
effect
antibiot
ebola
viru
entri
occur
fig
howev
compound
cell
pretreat
assay
show
host
cell
pretreat
teicoplanin
subsequ
wash
remov
drug
inhibitori
effect
ebolahiv
pseudotyp
virus
remain
fig
togeth
data
indic
target
teicoplanin
locat
host
cell
clarifi
molecular
mechan
teicoplanin
action
test
whether
teicoplanin
inhibit
entri
virus
abl
util
similar
intracellular
transport
rout
employ
ebola
virus
report
ebola
virus
sar
coronavirus
sarscov
need
transport
endolysosom
releas
genom
fig
therefor
hivlucsarscov
pseudotyp
virus
bear
protein
sarscov
gener
use
test
whether
entri
could
repress
teicoplanin
data
indic
teicoplanin
also
inhibit
entri
sarscov
fig
given
niemannpick
angiotensinconvert
enzym
repres
cell
receptor
ebola
virus
sarscov
respect
teicoplanin
inhibit
virus
necessari
clarifi
whether
ebola
virus
sarscov
share
cell
receptor
affin
follow
deplet
express
cell
use
sirna
cell
infect
ebola
sarscov
pseudotyp
virus
result
demonstr
knockdown
affect
infect
ebola
sarscov
pseudotyp
virus
wherea
convers
observ
follow
knockdown
fig
indic
two
virus
associ
specif
receptor
also
exclud
possibl
teicoplanin
inhibit
interact
virus
cell
receptor
event
follow
receptor
bind
taken
togeth
data
led
us
hypothes
target
teicoplanin
would
host
factor
requir
ebola
sarscov
infect
consid
interferoninduc
transmembran
protein
ifitm
repres
first
line
antivir
defens
cell
first
examin
effect
teicoplanin
express
ifitm
howev
data
show
teicoplanin
induc
express
ifitm
data
shown
examin
host
factor
requir
ebola
virus
sarscov
vsv
use
sirna
genomewid
haploid
genet
screen
sever
host
factor
essenti
ebola
viral
infect
identifi
accordingli
infect
cell
ebola
sarscov
vsvpseudotyp
virus
sirnamedi
knockdown
express
individu
host
factor
found
cathepsin
l
ctsl
requir
ebola
sarscov
infect
fig
rather
vsv
infect
result
impli
host
factor
might
target
teicoplanin
compon
hop
complex
mediat
homotyp
fusion
late
endosom
heterotyp
fusion
late
endosom
lysosom
investig
whether
teicoplanin
affect
transport
ebola
virus
inhibit
hop
complex
function
subsequ
disturb
endosom
matur
fusion
late
endosom
lysosom
dextran
uptak
assay
conduct
fig
found
within
h
uptak
dextranalexa
fluor
could
transport
lysosomeassoci
membran
protein
posit
lysosom
coloc
coeffici
dextran
influenc
sirna
knockdown
wherea
teicoplanin
exert
effect
fig
data
indic
teicoplanin
inhibit
transport
dextranalexa
fluor
therefor
unlik
teicoplanin
inhibit
entri
ebola
virus
affect
hop
complex
addit
conduct
virion
uptak
assay
demonstr
teicoplanin
inhibit
ebola
vsvpseudotyp
virion
uptak
h
postinfect
fig
e
f
data
indic
teicoplanin
affect
endocytosi
ebola
vsvpseudotyp
virion
least
earli
phase
addit
data
also
indic
except
hop
complex
teicoplanin
effect
host
factor
involv
process
virion
uptak
exclud
possibl
machineri
vesicl
transport
involv
inhibitori
effect
teicoplanin
assum
enzym
late
endosomelysosom
could
target
teicoplanin
proteolysi
glycoprotein
cathepsin
l
report
requir
membran
fusion
ebola
virus
sarscov
contract
cathepsin
b
requir
ebola
viru
infect
sarscov
infect
hypothes
cathepsin
l
rather
cathepsin
b
could
target
teicoplanin
end
examin
whether
teicoplanin
inhibit
enzymat
activ
cathepsin
l
fig
two
assay
measur
cathepsin
l
enzymat
activ
perform
show
teicoplanin
potent
inhibit
activ
cathepsin
l
dosedepend
manner
fig
b
e
consid
inhibitori
dose
teicoplanin
activ
cathepsin
l
higher
requir
ebola
viru
infect
inhibit
cell
viabil
assay
perform
confirm
inhibitori
effect
due
cytotox
fig
addit
compar
analysi
inhibitori
dose
teicoplanin
previous
report
cathepsin
l
inhibitor
zphetyr
tbu
diazomethyl
keton
ebola
viru
infect
conduct
demonstr
compound
inhibit
ebola
viru
infect
low
dose
dose
teicoplanin
requir
inhibit
ebola
entri
approxim
four
time
zphetyr
tbu
diazomethyl
keton
fig
tabl
similarli
dose
teicoplanin
requir
inhibit
enzymat
activ
cathepsin
l
also
approxim
four
time
greater
fig
b
e
tabl
data
indic
high
dose
teicoplanin
determin
requir
inhibit
cathepsin
l
enzymat
activ
could
due
rel
low
sensit
cathepsin
l
activ
assay
data
clearli
demonstr
consist
inhibit
viru
entri
inhibit
cathepsin
l
activ
support
conclus
target
molecul
teicoplanin
cathepsin
l
ebola
trvlp
system
simul
life
cycl
wildtyp
ebola
virus
larg
extent
appli
investig
whether
teicoplanin
glycopeptid
antibiot
homolog
dalbavancin
oritavancin
telavancin
vancomycin
also
inhibit
entri
ebola
trvlp
accordingli
plasmid
encod
renilla
luciferas
gp
transfect
cell
along
plasmid
express
rna
polymeras
np
l
viral
protein
produc
ebola
trvlp
fig
target
cell
also
pretransfect
np
l
plasmid
transcript
replic
ebola
viru
minigenom
activ
stimul
produc
infecti
ebola
trvlp
valu
teicoplanin
ebola
trvlp
entri
nm
condit
fig
addit
target
cell
pretransfect
plasmid
ebola
viral
minigenom
weakli
transcrib
replic
minim
product
infecti
trvlp
teicoplanin
entri
ebola
trvlp
nm
nonpretransfect
condit
fig
addit
also
examin
whether
homolog
teicoplanin
inhibit
ebola
trvlp
entri
data
demonstr
valu
dalbavancin
oritavancin
telavancin
ebola
trvlp
entri
respect
pretransfect
condit
fig
f
h
respect
nonpretransfect
condit
fig
e
g
howev
found
vancomycin
inhibit
ebola
trvlp
entri
either
condit
fig
j
k
valu
dalbavancin
oritavancin
telavancin
vancomycin
also
determin
data
shown
data
indic
homolog
might
share
similar
structur
indispens
inhibitori
effect
ebola
trvlp
entri
howev
vancomycin
would
expect
similar
structur
fig
data
demonstr
teicoplanin
inhibit
cathepsin
l
enzymat
activ
cathepsin
l
also
essenti
merscov
sarscov
entri
therefor
hypothes
teicoplanin
homolog
could
also
inhibit
entri
merscov
sarscov
data
illustr
valu
teicoplanin
dalbavancin
oritavancin
telavancin
merscov
entri
respect
fig
howev
vancomycin
inhibit
merscov
entri
fig
addit
valu
teicoplanin
dalbavancin
oritavancin
telavancin
entri
sarscov
respect
fig
howev
vancomycin
inhibit
entri
sarscov
fig
data
indic
glycopeptid
antibiot
except
vancomycin
exhibit
broad
antivir
activ
inhibitori
effect
cathepsin
l
studi
perform
high
throughput
screen
clinic
approv
drug
librari
identifi
teicoplanin
inhibit
entri
pseudotyp
virus
also
transcript
replicationcompet
trvlp
valu
teicoplanin
entri
ebola
trvlp
low
nm
wherea
teicoplanin
addit
teicoplanin
inhibit
entri
ebola
virus
differ
type
host
cell
includ
primari
human
umbil
vein
endotheli
cell
cell
hela
cell
cell
also
inhibit
entri
pseudotyp
virus
teicoplanin
glycopeptid
antibiot
isol
actinoplan
teichomyceticu
teicoplanin
contain
five
major
compon
form
complex
ctermin
subunit
lipid
ii
peptidoglycan
precursor
teicoplanin
bind
lipid
ii
inhibit
transglycosyl
transpeptid
lead
disturb
cell
wall
synthesi
gramposit
bacteria
recent
teicoplanin
report
inhibit
ebola
pseudoviru
infect
cell
cultur
consist
observ
teicoplanin
also
demonstr
effect
common
compon
use
envelop
ebola
virus
human
respiratori
syncyti
virus
nonenvelop
virus
howev
mechan
teicoplanin
inhibit
entri
ebola
remain
unresolv
elucid
molecular
mechan
underli
process
compar
entri
ebola
virus
sarscov
effect
teicoplanin
thereon
teicoplanin
repress
entri
ebola
virus
sarscov
requir
transport
endolysosom
deliv
genom
sever
host
factor
report
essenti
ebola
sarscov
viru
infect
identif
common
host
factor
requir
entri
ebola
virus
sarscov
would
like
help
clarifi
target
teicoplanin
data
demonstr
ctsl
indispens
entri
ebola
virus
sarscov
fig
elucid
via
dextran
uptak
assay
teicoplanin
affect
function
hop
complex
suggest
target
teicoplanin
cathepsin
l
support
result
two
cathepsin
l
enzymat
activ
assay
indic
teicoplanin
inde
inhibit
activ
cathepsin
l
explain
teicoplanin
inhibit
entri
ebola
virus
human
respiratori
syncyti
virus
shown
previou
studi
cathepsin
l
requir
infect
mechan
consid
cathepsin
l
also
requir
entri
merscov
teicoplanin
thu
repres
broad
viru
entri
inhibitor
addit
inhibitori
effect
teicoplanin
deriv
hcv
influenza
virus
flavivirus
fipv
sarscov
also
report
support
antivir
target
glycopeptid
antibiot
common
host
factor
teicoplanin
bind
lipid
ii
hypothes
might
interact
enzymat
domain
cathepsin
l
block
function
similar
report
inhibitori
effect
antimicrobi
peptid
cathepsin
l
specif
bind
site
teicoplanin
cathepsin
l
need
investig
molecular
dock
amino
acid
mutat
surfac
plasmon
reson
confirm
hypothesi
also
examin
effect
teicoplanin
homolog
dalbavancin
oritavancin
telavancin
vancomycin
entri
ebola
trvlp
pseudotyp
virus
data
demonstr
dalbavancin
oritavancin
telavancin
also
inhibit
entryof
pseudotyp
virus
howev
vancomycin
repress
infect
compar
structur
compound
found
glycopeptid
antibiot
inhibit
ebola
trvlp
pseudotyp
viru
entri
contain
hydrophob
group
amidogen
domain
aminosaccharid
group
might
play
import
role
interact
glycopeptid
antibiot
cathepsin
l
contrast
vancomycin
lack
hydrophob
group
might
reason
inhibit
viral
infect
fig
treatment
gramposit
bacteri
infect
clinic
teicoplanin
administ
intraven
intramuscularli
daili
follow
initi
load
dose
conveni
outpati
therapi
compar
vancomycin
first
discov
glycopeptid
antibiot
teicoplanin
better
toler
lower
nephrotox
summari
product
characterist
teicoplanin
show
complet
load
dose
regimen
gramposit
bacteri
infect
serum
concentr
teicoplanin
least
mgliter
time
higher
valu
teicoplanin
entri
ebola
virus
pseudotyp
virus
respect
toxic
glycopeptid
antibiot
quit
low
propos
glycopeptid
antibiot
might
use
clinic
ebolamerscovsarscov
infect
especi
case
emerg
requir
outbreak
sever
viral
infect
list
author
contribut
work
review
manuscript
n
z
pan
design
experi
perform
experi
j
z
x
z
f
h
peng
l
j
h
z
perform
differ
kind
virusrel
experi
q
w
l
c
b
c
l
carri
high
throughput
screen
food
drug
administrationapprov
drug
librari
n
z
h
z
contribut
idea
gener
experiment
design
manuscript
prepar
conceiv
project
